Is Egrifta (Tesamorelin) Legal in Kentucky?

HealthRX.com

Egrifta is FDA-approved and obtained by prescription

1.4 mgLabeled daily dose of Egrifta SV, injected under the skinSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 0.35 mLReconstituted volume for one daily Egrifta SV doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.28 mgLabeled daily dose of Egrifta WR, injected under the skinSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 0.16 mLReconstituted volume for one daily Egrifta WR doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.4 mgLabeled daily dose of Egrifta SV, injected under the skinSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • Federal status / FDA-approved prescription drug, first approved November 10, 2010 (BLA 022505) [1]
  • Approved use / excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]
  • Current products / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), labels dated July 29, 2026 [2][3]
  • Dosing / Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily; the two are not substitutable [2][3]
  • Compounding / tesamorelin is not on FDA's significant-risk bulk list and has no category-based statement [4][5][6]
  • HHS peptide draft / not among the six peptides named in the October 28, 2026 draft policy [7][8]
  • Sport / WADA prohibits tesamorelin at all times [9][10]

What Does FDA Approval Mean for Kentucky?

Egrifta (tesamorelin acetate) was first approved by FDA on November 10, 2010, under application BLA 022505 [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026, and both given as once-daily subcutaneous injections [2][3].

The only FDA-approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]. The label says tesamorelin is not indicated for weight loss management because it has a weight-neutral effect, and that long-term cardiovascular safety has not been established [2][3]. Tesamorelin is a growth hormone-releasing factor analog, not growth hormone itself [2].

Egrifta's federal status as a prescription drug is clear [1][2]. This page does not set out any Kentucky-specific rule on prescribing or dispensing tesamorelin.

Is Compounded Tesamorelin Legal in Kentucky?

Tesamorelin is not on FDA's page of bulk substances that may present significant safety risks when compounded [4]. It also appears in no category of FDA's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025) [5][6]. FDA has made no category-based statement about compounding it [4][5][6].

That is not the same as FDA approval of a compounded tesamorelin product. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8]. Egrifta contains tesamorelin acetate and is FDA-approved [1][2].

A separate HHS draft enforcement-discretion policy for compounded peptides, filed October 28, 2026, names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [7][8]. Tesamorelin is not one of them [7][8].

What Do the Labels Say About the Two Products?

Egrifta SV is the 2 mg-vial formulation. Its labeled dose is 1.4 mg, or 0.35 mL of the reconstituted solution, injected subcutaneously into the abdomen once daily [2]. Egrifta WR is the 11.6 mg-vial formulation. Its labeled dose is 1.28 mg, or 0.16 mL of the reconstituted solution, injected subcutaneously into the abdomen once daily [3]. The labels say Egrifta SV and Egrifta WR are not substitutable [3].

The labels list contraindications including pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis, and known hypersensitivity to tesamorelin or the product's excipients [2][3]. They also warn about glucose intolerance or diabetes, elevated IGF-1, fluid retention, hypersensitivity reactions and injection-site reactions [2][3].

Questions worth asking

Choose the questions you want to keep

Is Tesamorelin Banned in Sport?

WADA's Prohibited List names tesamorelin in S2.2.4, among growth hormone-releasing factors and their analogues [9]. It is prohibited at all times, in and out of competition, on the 2026 List and the 2027 List [9][10].

Is Egrifta (tesamorelin) legal in Kentucky?
Egrifta is an FDA-approved prescription drug, obtained by prescription under federal law [1][2]. Its only approved use is excess abdominal fat in HIV-infected adults with lipodystrophy [2][3].
Is compounded tesamorelin legal in Kentucky?
FDA has not placed tesamorelin on its significant-risk bulk list or in any category of its compounding lists, so it has made no category-based statement about compounding it [4][5][6]. A compounded tesamorelin product is still not FDA-approved [8].
Are Egrifta SV and Egrifta WR interchangeable?
No. The labels say they are not substitutable, and the doses differ: Egrifta SV is 1.4 mg daily and Egrifta WR is 1.28 mg daily [2][3].
Is tesamorelin legal for athletes?
WADA prohibits tesamorelin at all times and names it in S2.2.4 [9][10].
What is Egrifta approved for?
Only reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it is not indicated for weight loss [2][3].
Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. Official web page.
  8. Official web page.
  9. World Anti-Doping Agency.
  10. World Anti-Doping Agency.
Evidence overview for Is Egrifta (Tesamorelin) Legal in Kentucky?